Literature DB >> 32533632

Identification and characterization of a Triton X-100 replacement for virus inactivation.

Wen Luo1, Danielle Hickman1, Mandana Keykhosravani1, Joseph Wilson1, Jamie Fink1, Lihua Huang1, Dayue Chen1, Sean O'Donnell1.   

Abstract

Triton X-100 detergent treatment is a robust enveloped virus inactivation unit operation included in biopharmaceutical manufacturing processes. However, the European Commission officially placed Triton X-100 on the Annex XIV authorization list in 2017 because a degradation product of Triton X-100, 4-(1,1,3,3-tetramethylbutyl) phenol (also known as 4-tert-octylphenol), is considered to have harmful endocrine disrupting activities. As a result, the use of Triton X-100 in the European Economic Area (EEA) would not be allowed unless an ECHA issued authorization was granted after the sunset date of January 4, 2021. This has prompted biopharmaceutical manufacturers to search for novel, environment-friendly alternative detergents for enveloped virus inactivation. In this study, we report the identification of such a novel detergent, Simulsol SL 11W. Simulsol SL 11W is an undecyl glycoside surfactant produced from glucose and C11 fatty alcohol. We report here that Simulsol SL 11W was able to effectively inactive enveloped viruses, such as xenotropic murine leukemia virus (XMuLV) and pseudorabies virus (PRV). By using XMuLV as a representative enveloped virus, the influence of various parameters on the effectiveness of virus inactivation was evaluated. Virus inactivation by Simulsol SL 11W was effective across different clarified bioreactor harvests at broad concentrations, pH, and temperature ranges. Simulsol SL 11W concentration, temperature of inactivation, and treatment time were identified as critical process parameters for virus inactivation. Removal of Simulsol SL 11W was readily achieved by Protein A chromatography and product quality was not affected by detergent treatment. Taken together, these results have shown the potential of Simulsol SL 11W as a desirable alternative to Triton X-100 for enveloped virus inactivation that could be readily implemented into biopharmaceutical manufacturing processes.
© 2020 American Institute of Chemical Engineers.

Entities:  

Keywords:  Triton X-100; glycoside; virus inactivation

Year:  2020        PMID: 32533632     DOI: 10.1002/btpr.3036

Source DB:  PubMed          Journal:  Biotechnol Prog        ISSN: 1520-6033


  4 in total

1.  Integrated autolysis, DNA hydrolysis and precipitation enables an improved bioprocess for Q-Griffithsin, a broad-spectrum antiviral and clinical-stage anti-COVID-19 candidate.

Authors:  John S Decker; Romel Menacho-Melgar; Michael D Lynch
Journal:  Biochem Eng J       Date:  2022-03-12       Impact factor: 3.978

2.  Process steps for the fractionation of immunoglobulin (Ig) G depleted of IgA, isoagglutinins, and devoid of in vitro thrombogenicity.

Authors:  Josephine H Cheng; Yu-Wen Wu; Chen-Yun Wang; Sharon S Wu; Cheum L Hong; Karen W Chan; Leo X Liao; Xisheng Cao; Bin Wang; Thierry Burnouf
Journal:  Blood Transfus       Date:  2021-08-04       Impact factor: 3.443

3.  Supported Lipid Bilayer Platform for Characterizing the Membrane-Disruptive Behaviors of Triton X-100 and Potential Detergent Replacements.

Authors:  Negin Gooran; Bo Kyeong Yoon; Joshua A Jackman
Journal:  Int J Mol Sci       Date:  2022-01-14       Impact factor: 5.923

4.  Identification of compendial nonionic detergents for the replacement of Triton X-100 in bioprocessing.

Authors:  Alan K Hunter; Kamiyar Rezvani; Matthew T Aspelund; Guoling Xi; Dhanesh Gadre; Thomas Linke; Kang Cai; Sri Hari Raju Mulagapati; Tomasz Witkos
Journal:  Biotechnol Prog       Date:  2022-01-22
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.